Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96HP4

UPID:
OXND1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q96HP4; Q2HYC7; Q59FA4

BACKGROUND:
The Oxidoreductase NAD-binding domain-containing protein 1, identified by the unique identifier Q96HP4, is integral to the cellular oxidative-reduction mechanisms. It functions by mediating electron transfer in various metabolic pathways, highlighting its significance in energy metabolism and cellular defense against oxidative damage.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Oxidoreductase NAD-binding domain-containing protein 1 holds promise for the development of novel therapeutic approaches. Given its involvement in critical redox reactions, targeting this protein could offer new avenues for treating conditions linked to disrupted cellular redox balance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.